ACHP Statement on Drug Pricing
ACHP released a statement on drug pricing.
Category: Statement
ACHP Statement on CY2026 MA and Part D Rate Notice
ACHP commends the Trump Administration for finalizing policies in the 2026 MA and Part D Rate Notice that reflect higher care delivery costs and for taking another step toward reining in aggressive risk adjustment to boost competition.
ACHP Statement on Final CY2026 MA and Part D Rule
ACHP President and CEO Ceci Connolly released a statement in response to CMS’ final CY2026 Medicare Advantage and Part D rule.
ACHP Statement on Dr. Oz’s Confirmation as CMS Administrator
ACHP is grateful for its longstanding partnership with CMS and congratulates Dr. Mehmet Oz on his confirmation as CMS Administrator.
ACHP Statement on Dr. Makary’s Confirmation as FDA Commissioner
ACHP released a statement regarding the confirmation of Dr. Marty Makary as Commissioner of the U.S. Food and Drug Administration.
